FUS and etoposide treatment for midline brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This early-phase study tests whether focusing ultrasound (FUS) plus etoposide can help treat children and teens with diffuse midline glioma that affects the brainstem (pons) and/or thalamus, especially with an H3K27M change. Participants must have cancer that is getting worse and be healthy enough to safely receive study treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 4 and 21 years old
- Your tumor is a diffuse midline glioma in the pons and/or thalamus, or your tumor testing shows an H3K27M mutation
- Your cancer has started to progress (get worse) by scans and/or symptoms
- Your energy level is fairly good: at least 60 (Lansky if age 16 or younger, Karnofsky if older)
- Your blood counts and organ tests are in safe ranges (bone marrow, kidneys, liver)
- You have recovered from earlier cancer treatments and can stay on stable steroid and seizure-medicine doses for at least 1 week
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to treat a type of brain tumor called diffuse midline glioma. It uses focused ultrasound to open a tiny gap in the blood-brain barrier, which may help special immune cells (T-cells) reach and attack the tumor. The goal is to see if this combination is safe and helpful.
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests adding atovaquone to standard radiation therapy for children with aggressive brain tumors like high-grade glioma (a fast-growing brain cancer) or medulloblastoma. The goal is to see if this drug, which targets energy production in cancer cells, can make radiation work better.
This trial tests whether using focused ultrasound to temporarily open the blood-brain barrier can help chemotherapy (temozolomide) reach a brain tumor called diffuse midline glioma more effectively. The goal is to see if this procedure is safe and feasible in patients who have already completed radiation therapy.
This trial tests if combining focused ultrasound (which opens the blood-brain barrier) with the immunotherapy drug nivolumab can treat relapsed or progressive brainstem gliomas and other high-grade brain tumors in children and young adults.
Hear when a new Diffuse Intrinsic Pontine Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.